T-Cell Therapies offer enormous promise in the development of new approaches to treating cancer. A federal appeals court recently heard arguments in a patent dispute between two companies that have emerged as leaders in CAR-T technology for new cancer treatments. The patent relates to a treatment approach that uses specially altered T cells to fight cancer. In 2020 Juno Therapeutics won a $1 billion judgment against Gilead’s Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell Receptors.”



In this episode of the Harris Beach Podcast, partner Laura Smalley provides additional background on the case, analyzes the Circuit Court arguments, and provides her thoughts on the implications of the case and what might happen next.



Related Links: Laura Smalley Bio - http://bit.ly/2uoTz2FIntellectual Law Practice Group - https://bit.ly/30dLcCU

Ver todos los episodios